Summary:
Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an insufficient response to antidepressant treatment. Study will last approximately 22 weeks.
Qualified Participants Must:
• Be over the age of 65
•
Have had at least one previous depressive episode before the age of 60 years
•
Have had an inadequate response to at least one and no more than three antidepressant treatments during the current depressive episode
•
Have had depression that lasted at least 8 weeks
Qualified Participants May Receive:
Compensation for time and travel may be possible.